Pulmonx Corporation (LUNG)

USD 6.1

(-0.49%)

Market Cap (In USD)

240.87 Million

Revenue (In USD)

68.67 Million

Net Income (In USD)

-60.84 Million

Avg. Volume

317.7 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.46-14.835
PE
-
EPS
-
Beta Value
0.684
ISIN
US7458481014
CUSIP
745848101
CIK
1127537
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Steven S. Williamson
Employee Count
-
Website
https://pulmonx.com
Ipo Date
2020-10-01
Details
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

More Stocks